Skip to content
bretylium

Structure via PubChem · Public domain (PubChem)

EntityQ420026· pop 12· linked from 824 articles

Also known as ASL-603, bretylium tosylate, Bretylol®, 2-bromo-N-ethyl-N,N-dimethylbenzenemethanaminium, (2-bromobenzyl)ethyldimethylaminium, N-ethyl-N,N-dimethyl-2-bromobenzenemethanaminium, N-Ethyl-N,N-dimethyl-2-bromobenzenemethanaminium, (2-Bromobenzyl)ethyldimethylaminium

Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy.

In the Vinony graph

Vinony's link graph records 824 inbound references to bretylium, and connects out to valproic acid, antiarrhythmic agent and (RS)-baclofen.

It is catalogued under topics including 2-Bromophenyl compounds, Adrenergic release inhibitors and Antiarrhythmic agents.

Vinony links it to 11 Wikipedia language editions.

Chemical data

Formula
C11H17BrN+
Molecular weight
243.16 g/mol
IUPAC name
(2-bromophenyl)methyl-ethyl-dimethylazanium
SMILES
CC[N+](C)(C)CC1=CC=CC=C1Br
InChIKey
AAQOQKQBGPPFNS-UHFFFAOYSA-N
XLogP
2.8
Polar surface area
0 Ų
H-bond donors
0
H-bond acceptors
0
Formal charge
1

via PubChem

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Small molecule
First approval
1982
Admin. routes
parenteral

via ChEMBL · EBI

Research

1,652 papers

via PubMed

Wikidata facts

Mass
242.054437
Has use
medication
Show 5 more facts
subject has role
adrenergic antagonist
canonical SMILES
CC[N+](C)(C)CC1=CC=CC=C1Br
medical condition treated
heart conduction disease
Commons category
Bretylium
chemical formula
C₁₁H₁₇BrN⁺
Sources (5)

via Wikidata · CC0

~3 min read

Encyclopedic overview

3 sections
Contents
  • Uses
  • Experimental uses
  • References

Bretylium (also bretylium tosylate) is an antiarrhythmic agent. It blocks the release of noradrenaline from nerve terminals. In effect, it decreases output from the peripheral sympathetic nervous system. It also acts by blocking K+ channels and is considered a class III antiarrhythmic. The dose is 5–10 mg/kg and side effects are high blood pressure followed by low blood pressure and ventricular ectopy.

Originally introduced in 1959 for the treatment of hypertension. Its use as an antiarrhythmic for ventricular fibrillation was discovered and patented by Marvin Bacaner in 1969 at the University of Minnesota.

Excerpted from Wikipedia’s “bretylium” article, available under the CC BY-SA 4.0 licence.

Connections

Categories